<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525200</url>
  </required_header>
  <id_info>
    <org_study_id>ASSO OE-1</org_study_id>
    <secondary_id>EudraCT 2006-006647-31</secondary_id>
    <nct_id>NCT00525200</nct_id>
  </id_info>
  <brief_title>p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer</brief_title>
  <acronym>PANCHO</acronym>
  <official_title>p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer: A Multicenter, Randomized Controlled, Predictive Marker Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniela Kandioler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Austrian Society Of Surgical Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Hypothesis:

      PANCHO is a prospective randomized, predictive marker study, evaluating the interaction
      between the potential predictive marker 'p53 genotype' and response to induction chemotherapy
      in patients with esophageal cancer considered resectable.

      170 patients with measurable disease will be enrolled in this study. After testing the marker
      genotype (two genotypes: p53 normal or p53 mutant) patients will be stratified according to
      histological subtype only (adeno- or squamous cell carcinoma) and will be randomly assigned
      to receive 3 cycles of either 5-fluorouracil (5FU)/cisplatin or docetaxel monotherapy as
      neoadjuvant therapy. All patients will be rendered to subsequent surgery in order to assess
      both clinical and pathohistological response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PANCHO will test the hypothesis that p53 genotype is predictive for response to chemotherapy.
      The study uses the marker by treatment interaction design. In this design, we assume that the
      status of the marker splits the whole population into two distinct groups (p53 normal versus
      p53 mutant).

      Patients in each marker group are randomly assigned to two different treatments, and planned
      statistical analysis is to test whether one treatment is superior to the other within each
      marker group separately.

      The marker information but not the treatment is blinded to the patient and the investigators.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response (clinical and pathological) to neoadjuvant treatment in relation to p53 genotype</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete pathological response and relation to p53 genotype</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete tumor resection rate</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative morbidity and mortality</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free and overall survival and relation to p53 genotype</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fluoruracil, Cisplatinum</intervention_name>
    <description>5 FU 1000mg/m2; days 1-5; 3 cycles: q21
Cisplatin 80mg/m2; day 1; 3 cycles: q21</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75mg/m2, day 1; 3 cycles; q21</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological verification of esophageal cancer

          -  Presence of T2,T3,T4 or any N1 (except M1)

          -  Clinically measurable lesions according to RECIST criteria

          -  Males and females, age &gt;18 to 75 or older with WHO performance status 1

          -  No prior tumor therapy for esophageal cancer

          -  No other malignancy in history within 5 years before evaluation

          -  Performance status of 0-2 on ECOG scale

          -  Medical fitness (adequate for possible esophageal resection, adequate organ function:
             see protocol)

          -  Signed informed consent

          -  Males and females with reproductive potential must use an approved contraceptive
             method. Females with childbearing potential must have a negative serum pregnancy test
             within 7 days prior to study enrollment.

        Exclusion Criteria:

          -  Inoperability (technical or functional)

          -  Clinical stage cT1N0, any M1

          -  Treatment with any of the investigational drugs within the last 6 months

          -  Concurrent administration of any other tumor therapy

          -  Pregnancy, breast feeding

          -  Serious concomitant disorders that would compromise the safety of the patient or
             ability to complete the study

          -  Second primary malignancy that is clinically detectable at the time of consideration
             for study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniela Kandioler, Prof., MBA</last_name>
    <role>Study Chair</role>
    <affiliation>ASSO Representative, MUW, p53research Head</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johannes Zacherl, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Vienna, MUV</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Hejna, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>MUW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landesklinikum St. Pölten</name>
      <address>
        <city>St. Polten</city>
        <state>Lower Austria</state>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Wiener Neustadt</name>
      <address>
        <city>Wiener Neustadt</city>
        <state>Lower Austria</state>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesklinikum Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>8790</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Stankt Veit</city>
        <zip>9300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rudolfstiftung</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Franz Josef Spital</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanusch Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMZ OST</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://www.p53.at</url>
    <description>p53research group at the University of Vienna</description>
  </link>
  <reference>
    <citation>Kandioler D et al. p53 adapted neoadjuvant therapy for esophageal cancer: pilot study. JCO, vol 25, 18S: 206s</citation>
  </reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>December 20, 2012</last_update_submitted>
  <last_update_submitted_qc>December 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Daniela Kandioler</investigator_full_name>
    <investigator_title>Univ. Prof. Dr., MBA</investigator_title>
  </responsible_party>
  <keyword>predictive marker</keyword>
  <keyword>personalized therapy</keyword>
  <keyword>response assessment</keyword>
  <keyword>p53 genotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

